Development of Intravitreal Ranibizumab by Determining the Pathogenesis of Macular Edema With Retinal Vein Occlusion

Sponsor
Tokyo Medical University
Study ID
NCT02169648
Status
Unknown

Conditions

  • Branch Retinal Vein Occlusion
  • Central Retinal Vein Occlusion
  • Macular Edema

Eligibility Criteria

Sex
ALL
Age
30 Years - 90 Years
Healthy Volunteers
Not accepted

Interventions

  • ranibizumab — DRUG
    intravitreal injection of 0.50 mg (0.05ml) ranibizumab monthly as needed.

Study Details

The purpose of this study is to evaluate the efficacy of intravitreal ranibizumab by determining the pathogenesis of macular edema, which cause a direct effect on visual function. In particular, we focus on the correlation between the treatment effectiveness of ranibizumab and the role of the cytokines involved in the cause of macular edema.

Key Dates

First listed
Jun 23, 2014
Start date
Dec 31, 2013
Status verified
Jun 2014
Primary completion
Dec 31, 2015
Completion
Dec 31, 2015

Study Design

Enrollment
100 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: ranibizumab
    Experimental: Intravitreal injection of Ranibizumab

Primary Outcome Measure

Visual function by ranibizumab in macular edema with retnal vein occlusion [ Time Frame: one year ]

Central Contacts

Related Studies